Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.
Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Thursday, October 1, 2026 1 PM-2 PM ET
This presentation will explore the value of in-house CGP, offer insights into the benefits and drawbacks of incorporation, and provide information about important practical factors when considering in-house implementation of CGP.
Webinar presenter Allison M. Cushman-Vokoun, MD, PhD, FCAP, Medical Director, Molecular Diagnostics and Personalized Medicine Laboratory, Director, Division of Diagnostic Molecular Pathology and Human Genetics, Henry F. Krous Professor of Pathology, University of Nebraska Medical Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.
Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Athena Diagnostics offers new genetic tests to aid in the detection of several rare neurological disorders, including hereditary neuropathy, neuromuscular disease, epilepsy, and certain movement disorders. The lab-developed tests are available through Athena, a business of Quest Diagnostics.
Illumina’s TruSight Tumor, for NGS-based somatic variant detection in solid tumors, provides optimized amplicon-based library preparation of 26 oncogenes and tumor suppressor genes selected for their involvement in common solid tumors, including lung, colon, melanoma, gastric, and ovarian cancer.
Bio SB, through its partnership with ZytoVision of Germany, can now distribute a complete line of CE-approved chromogenic in situ hybridization and fluorescent in situ hybridization probes targeted for use in lung carcinomas. The line of lung carcinoma CISH and FISH probes includes ZytoLight ALK/EML4 Tricheck triple-color probe (Z-2144-200), ZytoDot EGFR/CEN7 dual-color probe (C-3033-400), and many more.
Biotix’s Tip Eject is a pipette tip reloading system that allows users to reload to Biotix racks without transfer devices. The packaging is translucent, which allows for easy tip identification while fully protecting tips from contamination due to contact and environmental particulates. Tip Eject cards are made from 100 percent recycled polypropylene, which helps labs reduce waste without sacrificing the quality of pipette tips.
Thermo Fisher Scientific’s Dionex UltiMate 3000 biocompatible rapid separation liquid chromatography system is designed to combine ultrahigh-performance liquid chromatography with the corrosion-resistant flow path required to analyze proteins, peptides, nucleic acids, and biotherapeutics.
NorDx, a member of MaineHealth, is the nation’s first clinical laboratory to acquire Sysmex America’s XN series automated hematology analyzers. The Sysmex XN-3000 configuration enables enhanced diagnostic capabilities and greater efficiency, which transforms NorDx into an accountable care laboratory model and shepherds in a new era of performance standards for quality care in New England, according to Stan Schofield, president of NorDx and senior VP of MaineHealth.
Tanner Scientific’s TN1500 tissue-embedding center is a user-friendly workstation that was designed with the input of hundreds of histology lab supervisors. The workstation features a four-line digital display for easy programming (all surface temperatures can be viewed and adjusted without the need to scroll), a fully adjustable cryoplate that can be placed on the right or left side, an adjustable-intensity bright LED light on a flexible tube, a 2.6-gallon tank capacity, an extra-large magnifying glass on a flexible tube, and more.
Medical’s highly specific p40 mouse monoclonal anti-p40 [BC28] demonstrated similar sensitivity and specificity to the company’s rabbit polyclonal p40, staining 97 percent (65/67) of cases of lung squamous cell carcinoma and zero percent (0/71) cases of lung adenocarcinoma, in an in-house study. In addition, the antibody has significantly less background and does not stain macrophages.
MolecularMD Corp. has entered into a license agreement to obtain rights to commercialize patent-pending intellectual property pertaining to use of LKB1 for diagnostic, prognostic, and predictive uses in humans in non-small cell lung cancer.
The African Society of Laboratory Medicine, working in conjunction with the CDC, Clinton Health Access Initiative, UNAIDS, and WHO/AFRO, has partnered with SoftTech Health in a program to network the laboratories continentwide with the LabQMS (Quality Management Software).
